## Indonesia

### Population 2018

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>845 (770–923)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>21 (8.9–38)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>24 (17–32)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>93 (67–99)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>5.3 (2.1–9.8)</td>
</tr>
</tbody>
</table>

### Estimates of TB burden*, 2018

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>845 (770–923)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>21 (8.9–38)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>24 (17–32)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>93 (67–99)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>5.3 (2.1–9.8)</td>
</tr>
</tbody>
</table>

### Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 2.4% (1.8–3.3)
- Previously treated cases: 13% (9–18)

### TB case notifications, 2018

- Total new and relapse: 563 879
  - % tested with rapid diagnostics at time of diagnosis: 12%
  - % with known HIV status: 37%
  - % pulmonary: 88%
  - % bacteriologically confirmed***: 50%
  - % children aged 0–14 years: 11%
  - % women: 37%
  - % men: 52%
- Number of patients with known HIV status who are HIV-positive: 10 174
  - on antiretroviral therapy: 4 082

### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 67% (61–73)
- TB patients facing catastrophic total costs: 12% (10–13)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 12% (10–13)
- Patients with known HIV status who are HIV-positive: 10 174
  - on antiretroviral therapy: 4 082

### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance***: 33%
- % of previously treated cases: 127%

### Laboratory-confirmed cases*

- MDR/RR-TB: 9 038, XDR-TB: 80
- MDR/RR-TB: 4 194, XDR-TB: 59

### Treatment success rate and cohort size

- New and relapse cases registered in 2017: 85% (425 819)
- Previously treated cases, excluding relapse, registered in 2017: 73% (4 934)
- HIV-positive TB cases registered in 2017: 69% (7 966)
- MDR/RR-TB cases started on second-line treatment in 2016: 48% (1 905)
- XDR-TB cases started on second-line treatment in 2016: 21% (61)

### TB preventative treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 10%
- % of children (aged < 5) household contacts of bacteriologically-confirmed**: 10% (9.3–11)

### TB financing, 2019

- National TB budget (US$ millions): 366
- Funding source: 30% domestic, 13% international, 57% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-03-19

Data: www.who.int/tb/data